Patents by Inventor James E. Egan
James E. Egan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230082272Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: ApplicationFiled: November 14, 2022Publication date: March 16, 2023Applicants: TargaGenix, Inc., The Research Foundation for the State University of New York, Northeastern UniversityInventors: James E. EGAN, Mansoor M. AMIJI, Iwao OJIMA
-
Patent number: 11497713Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: GrantFiled: December 19, 2018Date of Patent: November 15, 2022Assignees: TargaGenix, Inc., The Research Foundation for The State University of New York, Northeastern UniversityInventors: James E. Egan, Mansoor Amiji, Iwao Ojima
-
Publication number: 20200330557Abstract: Aspects of the disclosure relate to methods for treating cancer, e.g., by administering to a subject having cancer a primary cell-derived biologic with multiple cytokine components in combination with an antagonist of programmed cell death-ligand 1 (PD-L1) or programmed cell death 1 (PD-1) and/or with an antagonist of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Other aspects of the disclosure relate to methods of identifying a subject for treatment with an antagonist of PD-L1 or PD-1 and/or an antagonist of CTLA-4 or assessing the likelihood that a subject will be responsive to an antagonist of PD-L1 or PD-1 and/or an antagonist of CTLA-4.Type: ApplicationFiled: August 18, 2017Publication date: October 22, 2020Applicant: Brooklyn Immunotherapeutics LLCInventors: John W. Hadden II, Neil L. Berinstein, James E. Egan
-
Publication number: 20190183796Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Applicants: TargaGenix, Inc., The Research Foundation for The State University of New York, Northeastern UniversityInventors: James E. Egan, Mansoor Amiji, Iwao Ojima
-
Patent number: 10206875Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: GrantFiled: June 7, 2017Date of Patent: February 19, 2019Assignees: TargaGenix, Inc., The Research Foundation for the State University New York, Northeastern UniversityInventors: James E. Egan, Iwao Ojima, Mansoor M. Amiji, Galina Ivanovna Botchkina
-
Patent number: 9931378Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.Type: GrantFiled: April 13, 2016Date of Patent: April 3, 2018Assignee: IRX Therapeutics, Inc.Inventors: James E. Egan, Martin Kast, Harvey Brandwein
-
Publication number: 20180028442Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: ApplicationFiled: June 7, 2017Publication date: February 1, 2018Applicants: TargaGenix, Inc., The Research Foundation for the State University New York, Northeastern UniversityInventors: James E. EGAN, Iwao OJIMA, Mansoor M. AMIJI, Galina Ivanovna BOTCHKINA
-
Patent number: 9566331Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-?, and IFN-?, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.Type: GrantFiled: February 20, 2013Date of Patent: February 14, 2017Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy L. Signorelli, James E. Egan, Paul H. Naylor
-
Patent number: 9492519Abstract: The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at (east one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN ? (gamma) and TNF-? (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.Type: GrantFiled: July 12, 2013Date of Patent: November 15, 2016Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy L. Signorelli-Petrat, James E. Egan
-
Publication number: 20160303198Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.Type: ApplicationFiled: April 13, 2016Publication date: October 20, 2016Applicant: IRX Therapeutics, Inc.Inventors: James E. Egan, Martin Kast, Harvey Brandwein
-
Patent number: 9333238Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.Type: GrantFiled: December 8, 2010Date of Patent: May 10, 2016Assignee: IRX Therapeutics, Inc.Inventors: James E. Egan, Martin Kast, Harvey Brandwein
-
Publication number: 20140030217Abstract: The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at (east one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN ? (gamma) and TNF-? (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.Type: ApplicationFiled: July 12, 2013Publication date: January 30, 2014Inventors: John W. Hadden, Kathy L. Signorelli-Petrat, James E. Egan
-
Patent number: 8591956Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.Type: GrantFiled: August 8, 2011Date of Patent: November 26, 2013Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Theresa L. Whiteside-Nimick, James E. Egan, Kathy L. Signorelli-Petrat, Harvey Brandwein
-
Publication number: 20130243723Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-?, and IFN-?, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.Type: ApplicationFiled: February 20, 2013Publication date: September 19, 2013Applicant: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy L. Signorelli, James E. Egan, Paul H. Naylor
-
Publication number: 20120244117Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.Type: ApplicationFiled: December 8, 2010Publication date: September 27, 2012Applicant: IRX Therapeutics, IncInventors: James E. Egan, Martin Kast, Diane Da Silva, Harvey Brandwein
-
Publication number: 20120141512Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.Type: ApplicationFiled: August 8, 2011Publication date: June 7, 2012Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czytowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
-
Patent number: 7993660Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.Type: GrantFiled: November 26, 2008Date of Patent: August 9, 2011Assignee: IRx Therapeutics, Inc.Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czystowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
-
Publication number: 20090155291Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.Type: ApplicationFiled: November 26, 2008Publication date: June 18, 2009Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czystowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
-
Patent number: 6015176Abstract: A kit for installing a pickup box onto the frame of a chassis cab which contains a first bracket, a second bracket, a third bracket, a fourth bracket, a fifth bracket, and a sixth bracket. Each of the first two brackets has a substantially rectangular shape. Each of the third and fourth brackets is substantially L-shaped. Each of the fifth and sixth brackets has a substantially rectangular shape and contains an offset leg extending from one side thereof.Type: GrantFiled: March 22, 1999Date of Patent: January 18, 2000Inventor: James E. Egan